WASHINGTON – The FDA has been under the gun to qualify more biomarkers that could help accelerate the development of targeted therapies and track the progression of various diseases.
The community of individuals living with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, has endured many false hopes for promising therapies and is still waiting for the first disease-modifying drug.
WASHINGTON – Alnylam Pharmaceuticals Inc. used the forum of the American Academy of Neurology's (AAN) 67th annual meeting to disclose 12-month data from its ongoing phase II open-label extension (OLE) study of patisiran to treat transthyretin (TTR)-mediated amyloidosis in patients with familial amyloidotic polyneuropathy (FAP).
Efforts to develop remyelinating therapies in multiple sclerosis (MS) might have stolen some of the headlines heading into the American Academy of Neurology's (AAN) 67th Annual Meeting in Washington, but there are still plenty of data on traditional approaches to MS treatment on hand this week – some 500 presentations altogether – beginning with a slew of posters unveiled today.
The ginormous 67th American Academy of Neurology (AAN) annual meeting is in full swing, with more than 2,500 abstracts scheduled for presentation at scientific sessions during the week. If the emerging science abstracts – formerly called the "late-breakers" – are any indication, therapeutic advances targeting Alzheimer's disease (AD) will dominate conversations at AAN, although significant updates on approaches to treat epilepsy, multiple sclerosis and Parkinson's disease also are planned.
The FDA approved Corlanor (ivabradine) to reduce the risk of hospitalization for worsening heart failure (HF), marking the first win in Amgen Inc.'s small but ambitious cardiovascular (CV) franchise.
The FDA approved the first generic version of Copaxone (glatiramer acetate injection) to treat patients with relapsing forms of multiple sclerosis (MS), giving a green light to the abbreviated new drug application (ANDA) filed by Sandoz Inc. to market Glatopa (glatiramer acetate injection, formerly M356), formulated as a once-daily 20 mg/mL injection.
Researchers at the University of California at Berkeley have developed the prototype of a better mousetrap for in vitro drug studies that could someday transform the screening of cardiovascular drug candidates. The ultimate goal is to replace the use of animals to screen drug candidates for safety and efficacy, reducing both the time and cost to speed therapies through the development pipeline.
Researchers at the University of California at Berkeley have developed the prototype of a better mousetrap for in vitro drug studies that could someday transform the screening of cardiovascular drug candidates. The ultimate goal is to replace the use of animals to screen drug candidates for safety and efficacy, reducing both the time and cost to speed therapies through the development pipeline.
Top-line findings for Biogen Inc.'s anti-LINGO-1 monoclonal antibody candidate, BIIB033, that were released earlier this year gained a bit more credibility when additional data were disclosed today in advance of the company's presentations next week at the American Academy of Neurology's (AAN) 67th Annual Meeting in Washington.
